Neuropathic Ocular Pain (NOP) Market Insights, Epidemiology & Forecast 2026-2036: Urcosimod Emerges As A Promising Targeted NOP Therapy
Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Neuropathic Ocular Pain (NOP) - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
The neuropathic ocular pain (NOP) market is expected to grow across the seven major markets (7MM)-the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan-during the 2022-2036 study period. Market expansion is being supported by greater recognition of chronic ocular pain, improved diagnostic capabilities, increasing awareness of neuro-inflammatory mechanisms, and demand for therapies that address corneal nerve dysfunction rather than provide temporary symptomatic relief.
The report provides a comprehensive assessment of historical and forecast epidemiology, treatment practices, emerging therapies, market access, reimbursement, drug uptake, and commercial opportunities across the 7MM. It also evaluates market size, therapy-level revenue, patient share, competitive positioning, and growth projections through 2036.
Neuropathic Ocular Pain Epidemiology and Patient Burden
The exact prevalence of neuropathic ocular pain remains uncertain. According to the National Organization for Rare Disorders in 2025, the number of affected individuals has not been established. Underdiagnosis, inconsistent diagnostic criteria, and symptom overlap with dry eye disease and other ocular surface disorders continue to complicate epidemiological assessment.
Women account for a higher proportion of identified NOP cases and frequently experience associated conditions such as fibromyalgia and autoimmune disease. Autoimmune diseases affect approximately 5%-8% of the population, with women representing nearly 78% of affected individuals. This demographic pattern may contribute to the observed female predominance in ocular neuropathic pain.
The United States accounted for the highest number of NOP cases among the 7MM in 2025 and is projected to maintain its leading position during the forecast period. Europe and Japan are also expected to record greater diagnosed prevalence as physician awareness, corneal imaging, nerve assessment, and referral pathways improve.
Current Neuropathic Ocular Pain Treatment Landscape
There are currently no therapies approved by the US Food and Drug Administration specifically for neuropathic ocular pain. Clinical management generally combines ocular surface treatments, anti-inflammatory therapies, regenerative approaches, and systemic neuromodulators. Common options include lubricating eye drops, topical corticosteroids, cyclosporine, lifitegrast, autologous serum tears, platelet-rich plasma eye drops, gabapentin, and pregabalin.
These treatments may reduce inflammation, ocular discomfort, or nerve sensitization, but clinical responses remain variable. Many patients continue to experience persistent pain despite conventional dry eye treatment, reinforcing the need for disease-specific therapies with durable analgesic, anti-inflammatory, neuroprotective, and regenerative effects.
Key unmet needs in the neuropathic ocular pain market include:
- Delayed diagnosis caused by symptom overlap with dry eye disease and other ocular disorders Limited standardized diagnostic criteria and clinical pathways Absence of approved therapies targeting neuropathic mechanisms Persistent pain despite conventional ocular surface treatment Incomplete understanding of disease heterogeneity and pathophysiology Limited long-term evidence supporting treatment sequencing and combination therapy
Neuropathic Ocular Pain Pipeline and Competitive Landscape
The NOP clinical pipeline remains limited, creating a significant opportunity for ophthalmology companies and biotechnology developers. OKYO Pharma is among the principal companies advancing a targeted candidate for neuropathic corneal pain, a closely associated clinical indication within the broader neuropathic ocular pain landscape.
Urcosimod 0.05% (OK-101) is a lipid-conjugated chemerin peptide agonist targeting the ChemR23 receptor on ocular immune and nerve-associated cells. The therapy is being investigated for its potential to modulate ocular inflammation, reduce neuropathic pain, and support corneal nerve health.
OKYO Pharma has reported anti-inflammatory and pain-reducing activity in preclinical studies, alongside encouraging findings from Phase II clinical development. Urcosimod received FDA Investigational New Drug authorization and Fast Track designation for neuropathic corneal pain. According to the company's 2026 corporate presentation, a Phase IIb/III multiple-dose study was planned to begin in 2026, with topline results anticipated in the first half of 2027.
Recent urcosimod developments include:
- In March 2026, OKYO Pharma reported positive exploratory Phase IIa findings, including clinically meaningful pain reduction, quality-of-life improvement, and potential signals of corneal nerve restoration after 12 weeks of treatment. In January 2026, the FDA authorized a compassionate-use IND application for urcosimod in a patient with severe neuropathic corneal pain and limited treatment options. In December 2025, the company reported significant pain reduction and favorable changes in corneal nerve structure compared with placebo in a Phase II study. In September 2025, OKYO Pharma announced plans to advance urcosimod into multiple-dose development following proof-of-concept results and continued regulatory discussions under Fast Track designation.
Neuropathic Ocular Pain Market Drivers and Outlook
The neuropathic ocular pain market is gradually shifting from conventional symptom management toward therapies addressing neuro-inflammation, peripheral nerve dysfunction, corneal nerve damage, and central pain sensitization. This transition is expected to influence prescribing practices, clinical development priorities, and investment across the ophthalmic pain market.
Major growth drivers include increasing recognition of chronic ocular pain, rising prevalence of dry eye and autoimmune conditions, advances in corneal confocal microscopy and nerve assessment, broader use of multidisciplinary treatment, and growing interest in disease-specific drug development. The absence of an FDA-approved NOP therapy also creates opportunities for candidates capable of demonstrating clinically meaningful pain reduction and functional improvement.
Relevant therapeutic classes include ChemR23 agonists and anti-inflammatory peptide therapies, calcineurin inhibitors, T-cell-mediated inflammation modulators, nerve growth factor stimulators, regenerative treatments, systemic neuromodulators, and topical corticosteroids. Conventional lubricants and anti-inflammatory agents currently account for substantial treatment use, while regenerative, neuroprotective, and pain-modulating therapies are expected to shape future innovation.
Urcosimod may achieve comparatively strong uptake if future trials confirm its efficacy, safety, durability, and potential impact on corneal nerve health. Adoption will also depend on regulatory approval, pricing, reimbursement, physician education, diagnostic standardization, and differentiation from existing off-label treatments.
Market Access, Pricing, and Reimbursement
The report assesses country-specific market access, reimbursement, out-of-pocket costs, affordability programs, and insurance coverage. Pricing decisions for emerging NOP therapies are expected to reflect clinical benefit, treatment duration, target population, comparator costs, and the ability to reduce healthcare utilization associated with refractory ocular pain.
Analogue assessment and cost-effectiveness analysis will be particularly important for therapies entering a market currently dominated by off-label and supportive treatments. Manufacturers will need robust evidence demonstrating pain reduction, functional improvement, quality-of-life benefits, treatment durability, and value relative to established clinical practice.
Expert Analysis and Strategic Market Intelligence
The research incorporates primary insights from ophthalmology experts, clinicians, researchers, and other specialists across the 7MM. More than 10 key opinion leaders were contacted, with interviews conducted with over six experts. Institutions approached included the University of Mississippi Medical Center, the University of Bologna, and Teikyo University School of Medicine.
Expert perspectives were used to assess diagnostic practices, epidemiology, patient adherence, therapy switching, prescribing behavior, market access barriers, emerging drug adoption, and unresolved clinical needs. The report also applies SWOT and conjoint analyses to evaluate competitive positioning and rank emerging therapies according to efficacy, safety, administration, treatment frequency, development stage, probability of success, and addressable patient population.
Report Coverage
- Neuropathic ocular pain epidemiology and patient population forecasts across the 7MM Historical and forecast NOP market analysis from 2022 to 2036 Current treatment practices and evolving therapeutic algorithms Neuropathic ocular pain pipeline analysis and product profiles Drug uptake, peak patient share, and therapy-level sales forecasts Competitive landscape, pricing trends, and analogue assessment Market access, reimbursement, and affordability analysis Unmet needs, treatment addressable market, and commercial opportunities SWOT analysis, conjoint analysis, and key opinion leader insights
Reasons to Access the Report
The report supports pharmaceutical companies, biotechnology developers, investors, healthcare consultants, and other stakeholders seeking to understand the future of the neuropathic ocular pain therapeutics market. Its epidemiology-based, bottom-up forecasting methodology connects patient burden with diagnosis trends, treatment eligibility, drug adoption, and product-level revenue potential.
By examining regional opportunities, competitive threats, clinical development, treatment preferences, and market access challenges, the analysis enables stakeholders to strengthen development strategies, prioritize pipeline assets, prepare commercialization plans, and identify opportunities in an underserved ophthalmic pain market.
Overall, the neuropathic ocular pain market is positioned for measured growth through 2036. Greater diagnostic recognition, increasing research into ocular neuro-inflammation, and progress in targeted therapies are expected to transform the treatment landscape. The United States is projected to retain the largest market share, while Europe and Japan offer expanding opportunities as clinical awareness and therapeutic innovation continue to advance.
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment